Sodium Carbonate → 5-{8-[6-(4-Isopropyl-piperazin-1-yl)-pyridin-3-ylamino]-imidazo[1,2-a]pyrazin-5-yl}-2,3-dihydro-isoindol-1-one

HRID 1921839Notes

Reaction equation

HRID 1921839 reaction equation
[N:1]1(C2C=[CH:11][C:10]([NH:13][C:14]3[C:15]4[N:16]([CH:30]=[CH:31][N:32]=4)[C:17]([C:20]4[CH:21]=[C:22]5[C:26](=[CH:27][CH:28]=4)[C:25](=[O:29])[NH:24][CH2:23]5)=[CH:18][N:19]=3)=[CH:9][CH:8]=2)CCOCC1.BrC1N2C=CN=C2C(NC2C=[N:46][C:47]([N:50]3[CH2:55][CH2:54][N:53]([CH:56]([CH3:58])[CH3:57])[CH2:52][CH2:51]3)=CC=2)=NC=1.CC1(C)C(C)(C)OB(C2C=C3C(=CC=2)C(=O)NC3)O1.C([O-])([O-])=O.[Na+].[Na+]>O1CCOCC1.C1C=CC([P]([Pd]([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)[P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)=CC=1>[NH3:1].[CH:56]([N:53]1[CH2:52][CH2:51][N:50]([C:47]2[N:46]=[CH:11][C:10]([NH:13][C:14]3[C:15]4[N:16]([CH:30]=[CH:31][N:32]=4)[C:17]([C:20]4[CH:21]=[C:22]5[C:26](=[CH:27][CH:28]=4)[C:25](=[O:29])[NH:24][CH2:23]5)=[CH:18][N:19]=3)=[CH:9][CH:8]=2)[CH2:55][CH2:54]1)([CH3:58])[CH3:57]

Participants

8

Reactant 4

HCID 10340Sodium CarbonateHCID 219557955-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-oneHCID 573939935-[8-(4-Morpholin-4-yl-phenylamino)-imidazo[1,2-a]pyrazin-5-yl]-2,3-dihydro-isoindol-1-oneHCID 59023102(5-Bromo-imidazo[1,2-a]pyrazin-8-yl)-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-amine

Product 2

HCID 222AmmoniaHCID 590230745-{8-[6-(4-Isopropyl-piperazin-1-yl)-pyridin-3-ylamino]-imidazo[1,2-a]pyrazin-5-yl}-2,3-dihydro-isoindol-1-oneYield 50%

Reagents, catalysts & solvents 2

HCID 178418397HCID 178418397, compoundCatalystHCID 312751,4-DioxaneSolvent

Procedure

In the same way as described for Compound 178, step 4, using (5-bromo-imidazo[1,2-a]pyrazin-8-yl)-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-amine (0.05 g, 0.12 mmol), 5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-2,3-dihydro-isoindol-1-one (0.056 g, 0.22 mmol), 1.5M Na2CO3 (0.64 mL, 0.96 mmol) and Pd(PPh3)4 (0.042 g, 0.36 mmol) in dioxane (2 mL). Purification using silica gel column chromatography, eluting with DCM followed by 99:1 and 97:3 DCM:NH3 (7M in MeOH), affords the title compound as a yellow solid (28 mg, 50%). Conversion into the mesylate salt, as described for Compound 178, step 4, affords the title compound as a yellow solid (32 mg, 95%). LCMS: Rt 2.70 min (92%); m/z (APCI) 469 (M+H)+; 1H-NMR (400 MHz, d6-DMSO) δ (ppm) 1.34 (6H, d), 2.34 (3H, s, MsOH), 3.10-3.21 (4H, m), 3.57-3.59 (3H, m), 4.43 (2H, d), 4.52 (2H, s), 7.08 (1H, d), 7.52 (1H, s), 7.77-7.94 (4H, m), 8.07 (1H, s), 8.30 (1H, d), 8.75 (1H, s), 8.83 (1H, br s), 9.34 (1H, br s), 9.88 (1H, br s).

Workup

  1. customPurification
  2. washeluting with DCM

Sources & evidence

ORD record
ord-3151ebb5f83c48eea9ddf3d6aeb4e6fa
Source dataset
uspto-grants-2012_05
Patent number
US08173656B2

Reaction notes

Loading…